explore -WSS

explore

author：hotspot 2025-09-29 00:38:42 - browse：3

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Change Healthcare can notify patients about the breach, HHS says

hotspot

WSS

Poland's lawmakers approve a divisive law on Russian influence

ASCO: AstraZeneca says CAR

Teacher posts viral 'school supply rant' with advice for parents

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Wikipedia

explore

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Let's speed up science by embracing open access publishing

Wildfire smoke exposes gaps in outdoor worker protections

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Medicare details structure of new drug price negotiation program

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

At least 13 dead in Texas as scorching temps continue

Innovation in antibiotics is ailing. 'Brain drain' may kill it

George Santos makes 1st court appearance after pleading not guilty to 13 counts

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Wikipedia

Trump team launching legal defense fund to help pay legal bills

Intellia reports positive results for its CRISPR

FDA's Pazdur wants cancer trials to range beyond China alone

Campaign finance charge dropped from case against Sam Bankman

With trial win, GSK could get blood cancer drug back on market

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

explore

hotspot

focus

entertainment